DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Atrasentan
Atrasentan
14-114
Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
Addition of Atrasentan to Renin-Angiotensin System Blockade Reduces Albuminuria in Diabetic Nephropathy
G Protein-Coupled Receptors
Beacon of Hope Summer 2013 • No. 115 Some Folks, When They Want To
Glomerular Hyperfiltration in Diabetes
Effects of Insulin Combined with Metformin on Serum Cystatin C, Homocysteine and Maternal and Neonatal Outcomes in Pregnant Women with Gestational Diabetes Mellitus
ALIGN Study) Hiddo J
Novel Tracers and Their Development for the Imaging of Metastatic Prostate Cancer*
Download the Information on Specific Be Widely Applied
A Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Study Of
The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy
Der Einfluss Der VO (EG) 1901/2006 Auf Den Off-Label Use in Der Neonatologie“
Lessons Learned
Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Atrasentan: an Endothelin Receptor Antagonist for Refractory Prostate Cancer1
Stembook 2018.Pdf
Inhibitors & Agonists Compound Screening Libraries
Medicines in Development for Diabetes
Top View
Antioxidants in Kidney Diseases: the Impact of Bardoxolone Methyl
Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy
Epigenetic Modifiers As Potential Therapeutic Targets in Diabetic
A Turning Point for Chronic Kidney Disease in Diabetes
Article Predictors of Atrasentan-Associated Fluid
Endothelin-Receptor Antagonists for Diabetic Nephropathy: a Meta-Analysis WENMING YUAN,1 YI LI,2 JI WANG,3 JING LI,3 SHENJU GOU1 and PING FU1
(SONAR) Trial: a Cet Diabetes Endocrinol
The Selective Type a Endothelin Antagonist Atrasentan Reduces
Clinical Trials with Endothelin Receptor Antagonists: What Went Wrong and Where Can We Improve?☆
The Role of Calcitonin Gene-Related Peptide in the Endothelin-1 Mediated Pain Perception
Wo 2007/119214 A2
Pharmacology and Toxicology
Targeting Neuroendocrine Prostate Cancer: Molecular and Clinical
Travere Therapeutics R&D Day 2020
Anti-COVID-19 Compound Library (96-Well)
WO 2015/127416 Al 27 August 2015 (27.08.2015) P O P C T
Diabetic Kidney Disease State-Of-The-Art Circa 2017 Katherine R
Clinical Trials with Endothelin Receptor Antagonists: What Went Wrong and Where Can We Improve?☆
Clinical Study Protocol M11-352 a Randomized, Multicountry
The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy
Late Breaking Abstracts
GLP-1 Receptor Agonists and Diabetic Kidney Disease: a Call of Attention to Nephrologists
The Leading Source of Diabetes Business News Forward
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Endocrinology
Clinical Trials with Endothelin Receptor Antagonists: What Went Wrong and Where Can We Improve?☆
WO 2011/012715 Al
WO 2012/170676 Al 13 December 2012 (13.12.2012) P O P C T
Antioxidants in Kidney Diseases: the Impact of Bardoxolone Methyl
Atrasentan Reduces Albuminuria by Restoring the Glomerular Endothelial Glycocalyx Barrier in Diabetic Nephropathy
2016 Medicines in Development for Diabetes and Related Conditions
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
Clinical Study Protocol M12-919 a Multicenter, Single-Arm Study of The
Datasheet Inhibitors / Agonists / Screening Libraries a DRUG SCREENING EXPERT